Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV maintenance therapy in pediatric ulcerative colitis
2023-509018-12-00Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (2 arms), sponsored by Takeda. Primary endpoint: Clinical remission at Week 54. Started Jun 2024; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509018-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509018-12-00.